Publicaciones en colaboración con investigadores/as de University of Oxford (43)

2022

  1. Clinical trials in pediatric ALS: a TRICALS feasibility study

    Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, Vol. 23, Núm. 7-8, pp. 481-488

  2. Imitation of β-lactam binding enables broad-spectrum metallo-β-lactamase inhibitors

    Nature Chemistry, Vol. 14, Núm. 1, pp. 15-24

  3. Stromal oncostatin M cytokine promotes breast cancer progression by reprogramming the tumor microenvironment

    Journal of Clinical Investigation, Vol. 132, Núm. 7

2021

  1. Association of Variants in the SPTLC1 Gene with Juvenile Amyotrophic Lateral Sclerosis

    JAMA Neurology, Vol. 78, Núm. 10, pp. 1236-1248

  2. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  3. Heterogeneous contributions of change in population distribution of body mass index to change in obesity and underweight

    eLife, Vol. 10

  4. Pervasive transmission of a carbapenem resistance plasmid in the gut microbiota of hospitalized patients

    Nature Microbiology, Vol. 6, Núm. 5, pp. 606-616

  5. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

    The Lancet, Vol. 397, Núm. 10269, pp. 99-111

  6. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

    The Lancet, Vol. 397, Núm. 10277, pp. 881-891

2020

  1. Contact isolation versus standard precautions to decrease acquisition of extended-spectrum β-lactamase-producing Enterobacterales in non-critical care wards: a cluster-randomised crossover trial

    The Lancet Infectious Diseases, Vol. 20, Núm. 5, pp. 575-584

  2. Incendiary leptin

    Nutrients, Vol. 12, Núm. 2

  3. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

    The Lancet, Vol. 396, Núm. 10267, pp. 1979-1993

2018

  1. Erratum for Brunschwig et al., "UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria" (Antimicrobial Agents and Chemotherapy (2018) 62:9 (e00012-18) DOI: 10.1128/AAC.00012-18)

    Antimicrobial Agents and Chemotherapy

  2. Genome-wide Analyses Identify KIF5A as a Novel ALS Gene

    Neuron, Vol. 97, Núm. 6, pp. 1268-1283.e6

  3. Uct943, a next-generation plasmodium falciparum pi4k inhibitor preclinical candidate for the treatment of malaria

    Antimicrobial Agents and Chemotherapy, Vol. 62, Núm. 9

  4. Ultrasound-mediated cavitation-enhanced extravasation of mesoporous silica nanoparticles for controlled-release drug delivery

    Chemical Engineering Journal, Vol. 340, pp. 2-8

2017

  1. A new subfamily classification of the leguminosae based on a taxonomically comprehensive phylogeny

    Taxon, Vol. 66, Núm. 1, pp. 44-77

  2. A tetraoxane-based antimalarial drug candidate that overcomes PfK13-C580Y dependent artemisinin resistance

    Nature Communications, Vol. 8

  3. Hundreds of dual-stage antimalarial molecules discovered by a functional gametocyte screen

    Nature Communications, Vol. 8

  4. Probing supramolecular protein assembly using covalently attached fluorescent molecular rotors

    Biomaterials, Vol. 139, pp. 195-201